UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 230

Sortiert nach

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

Therapeutic advances in neurological disorders, 2017-10, Vol.10 (10), p.343-359

2017

Link zum Volltext

Verfügbarkeit prüfen

Molecular biomarkers in multiple sclerosis

Journal of neuroinflammation, 2019-12, Vol.16 (1), p.272-272, Article 272

2019

Link zum Volltext

Verfügbarkeit prüfen

A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition

Journal of neurology, 2021-04, Vol.268 (4), p.1210-1221

2021

Link zum Volltext

Verfügbarkeit prüfen

The role of TH17 cells in multiple sclerosis: Therapeutic implications

Autoimmunity reviews, 2020-10, Vol.19 (10), p.102647, Article 102647

2020

Link zum Volltext

Verfügbarkeit prüfen

Digital Twins for Multiple Sclerosis

Frontiers in immunology, 2021-05, Vol.12, p.669811-669811

2021

Link zum Volltext

Verfügbarkeit prüfen

How to reduce the delay of diagnosing secondary progression in multiple sclerosis

Multiple sclerosis, 2021-04, Vol.27 (4), p.646-647

2021

Link zum Volltext

Verfügbarkeit prüfen

Natalizumab during pregnancy and lactation

Multiple sclerosis, 2018-10, Vol.24 (12), p.1627-1634

2018

Link zum Volltext

Verfügbarkeit prüfen

Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors

Multiple sclerosis, 2013-11, Vol.19 (13), p.1792-1799

2013

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

Lancet neurology, 2017-03, Vol.16 (3), p.189-199

2017

Link zum Volltext

Verfügbarkeit prüfen

The need for a strategic therapeutic approach: multiple sclerosis in check

Therapeutic Advances in Chronic Disease, 2022-01, Vol.13, p.20406223211063032-20406223211063032

2022

Link zum Volltext

Verfügbarkeit prüfen

Differentiating societal costs of disability worsening in multiple sclerosis

Journal of neurology, 2020-04, Vol.267 (4), p.1035-1042

2020

Link zum Volltext

Verfügbarkeit prüfen

Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey

Therapeutic advances in neurological disorders, 2016-07, Vol.9 (4), p.250-263

2016

Link zum Volltext

Verfügbarkeit prüfen

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis

Frontiers in immunology, 2021-06, Vol.12, p.701752-701752

2021

Link zum Volltext

Verfügbarkeit prüfen

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients

International journal of molecular sciences, 2022-11, Vol.23 (22), p.13759

2022

Link zum Volltext

Verfügbarkeit prüfen

Building digital patient pathways for the management and treatment of multiple sclerosis

Frontiers in immunology, 2024, Vol.15, p.1356436-1356436

2024

Link zum Volltext

Verfügbarkeit prüfen

S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review

Therapeutic Advances in Neurological Disorders, 2022-01, Vol.15, p.175628642211331-17562864221133163

2022

Link zum Volltext

Verfügbarkeit prüfen

Data Collection in Multiple Sclerosis: The MSDS Approach

Frontiers in neurology, 2020-06, Vol.11, p.445-445

2020

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs

International journal of molecular sciences, 2021-08, Vol.22 (15), p.8042

2021

Link zum Volltext

Verfügbarkeit prüfen

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice

Frontiers in neurology, 2020-08, Vol.11, p.905-905

2020

Link zum Volltext

Verfügbarkeit prüfen

Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses

Frontiers in immunology, 2022-07, Vol.13

2022

Link zum Volltext

Verfügbarkeit prüfen

Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients

International journal of molecular sciences, 2022-10, Vol.23 (20), p.12361

2022

Link zum Volltext

Verfügbarkeit prüfen

Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients

Proceedings of the National Academy of Sciences - PNAS, 2020-09, Vol.117 (35), p.21512-21518

2020

Link zum Volltext

Verfügbarkeit prüfen

Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis

Frontiers in immunology, 2024-06, Vol.15, p.1404316

2024

Link zum Volltext

Verfügbarkeit prüfen

Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use

Neurology, 2022-11, Vol.99 (19), p.868

Ziemssen, Tjalf

2022

Link zum Volltext

Verfügbarkeit prüfen

Should We Use Clinical Tools to Identify Disease Progression?

Frontiers in neurology, 2021-01, Vol.11, p.628542-628542

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 230

Suche als RSS-Feed

Aktive Filter

PublikationsformBerichte

ThemaMultiple Sclerosis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(219)
Mit Volltextzugriff
(225)

Publikationsform

Artikel
(229)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(213)
Life Sciences & Biomedicine
(208)
Neurosciences & Neurology
(135)
Clinical Neurology
(113)
Humans
(94)
Neurosciences
(81)
Patients
(65)
Neurology
(57)
Female
(49)
Male
(46)
Adult
(43)
Clinical Trials
(29)
Immunology
(29)
Middle Aged
(29)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(28)
Quality Of Life
(28)
Magnetic Resonance Imaging
(25)
Medicine
(25)
Monoclonal Antibodies
(25)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

Molecular biomarkers in multiple sclerosis

A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition

The role of TH17 cells in multiple sclerosis: Therapeutic implications

Digital Twins for Multiple Sclerosis

How to reduce the delay of diagnosing secondary progression in multiple sclerosis

Natalizumab during pregnancy and lactation

Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

The need for a strategic therapeutic approach: multiple sclerosis in check

Differentiating societal costs of disability worsening in multiple sclerosis

Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients

Building digital patient pathways for the management and treatment of multiple sclerosis

S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review

Data Collection in Multiple Sclerosis: The MSDS Approach

Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice

Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses

Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients

Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients

Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis

Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use

Should We Use Clinical Tools to Identify Disease Progression?

Aktive Filter

Suchergebnisse filtern